Literature DB >> 3132381

Comparative in vitro activity of the new quinolone fleroxacin (RO 23-6240).

G Verschraegen1, G Claeys, A M Van den Abeele.   

Abstract

RO 23-6240 (fleroxacin), pefloxacin, augmentin, cefaclor, cef-uroxime, ceftazidime, vancomycin, piperacillin and amikacin were tested against a wide variety of gram-positive and gram-negative bacteria. The MICs of fleroxacin were very similar to those of pefloxacin. Against all the bacterial groups tested, the quinolones compared favorably with the other antimicrobials tested, particularly against the more resistant species such as Corynebacterium group JK and D2 and methicillin-resistant staphylococci.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132381     DOI: 10.1007/bf01962177

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  7 in total

1.  Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.

Authors:  R Wise; B Kirkpatrick; J Ashby; D J Griggs
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

2.  In vitro activity of the new 4-quinolone compound Ro 23-6240.

Authors:  A M Clarke; S J Zemcov
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267

3.  In-vitro activity of pefloxacin against micro-organisms multiply resistant to beta-lactam antibiotics and aminoglycosides.

Authors:  L Verbist
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

4.  In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone.

Authors:  N X Chin; D C Brittain; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

5.  The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.

Authors:  A King; K Shannon; I Phillips
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

6.  Activity of ciprofloxacin against multiply resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, and group JK corynebacteria.

Authors:  F R Venezio; W Tatarowicz; C A DiVincenzo; J P O'Keefe
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

7.  The comparative in-vitro activity of pefloxacin.

Authors:  A King; I Phillips
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

  7 in total
  6 in total

1.  In vitro activity of 79 antimicrobial agents against Corynebacterium group D2.

Authors:  J A García-Rodriguez; J E García Sánchez; J L Muñoz Bellido; T Nebreda Mayoral; E García Sánchez; I García García
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

2.  Cross-resistance and cross-susceptibility between fluoroquinolone agents.

Authors:  A L Barry; P C Fuchs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

Review 3.  Fleroxacin clinical pharmacokinetics.

Authors:  A E Stuck; D K Kim; F J Frey
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 4.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 5.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

Review 6.  Developments in quinolones. Bacteriology, pharmacokinetics and initial clinical experience of several investigational quinolone derivatives.

Authors:  R Janknegt; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1989-04-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.